Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: Methods of treating cancer related conditions using anamorelin are described.

Abstract: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H2 receptor antagonist, a serotonin 5-HT4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.

Abstract: The present invention relates to a method of treating cancer in a subject. The method comprises administering to a subject suffering from cancer a therapeutically effective amount of a 24-hydroxylase inhibitor in combination with a second amount of a suitable cancer therapeutic. The 24-hydroxylase inhibitor can be coadministered with a chemotherapeutic agent, such an antitumor antibiotic (e.g., mitoxantrone or bleomycin), an alkylating agent (e.g., estramustine or melphalan), a plant alkaloid (e.g., taxenes such as paclitaxel or docetaxel or vinca alkaloids such as vincristine or vinblastine) or a combination thereof. In additional therapy, the 24-hydroxylase inhibitor can be coadministered as an adjuvant to radiation therapy, such as an external beam irradiation or a radioisotope therapy, such as radiopharmaceutical therapy. Further, the 24-hydroxylase inhibitor can be coadministered as part of a combination therapy that includes hormonal ablation.

Abstract: The present invention relates to a method of treating cancer in a subject. The method comprises administering to a subject suffering from cancer a therapeutically effective amount of a 24-hydroxylase inhibitor. In certain embodiments, the 24-hydroxylase inhibitor can be coadministered with calcitriol.

Abstract: The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event is a cardiovascular event (e.g., myocardial infarction). In another embodiment, the vascular event is a cerebrovascular event (e.g., stroke (such as transient ischemic attacks (TIAs)). In yet another embodiment the vascular event is a peripheral vascular event (e.g., intermittent claudication). The method comprises administering a therapeutically effective amount of at least one growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.